Genor Biopharma reports increase in issued shares

Genor Biopharma Holdings Limited reported a total increase of 1,998,096 in its issued shares (excluding treasury shares) for the month ended 30 September 2025. This brings the total number of issued shares to 528,291,792. The company's authorised/registered share capital remains at 1,000,000,000 ordinary shares with a par value of USD 0.00002 per share, totaling USD 20,000.

The increase in issued shares primarily stems from the exercise of share options under various plans. The Pre-IPO Share Option Plan saw 77,000 new shares issued, while the Post-IPO Share Option Plan resulted in 330,375 new shares. Additionally, the 2023 Share Option Plan contributed 906,596 new shares from exercises. Total funds raised from the exercise of options during the month amounted to HK$1,943,163.35.

Furthermore, the company issued 684,125 new ordinary shares through other agreements, specifically related to Restricted Share Unit (RSU) plans, including grants from 2021, 2022, and 2023. No treasury shares were transferred out during the month.